Heartgenetics signs commercial agreement with Agena Bioscience

HeartGenetics and Agena Bioscience signed a commercial partnership to bring affordable genetic testing to the market.

HeartGenetics and Agena Bioscience announced today a co-promotion agreement leveraging Agena ’s MassARRAY® DX clinical diagnostics technology with HeartGenetics’ CE-IVD marked products for cardiovascular testing.

As a leader in genetic tests and computational tools designed to support clinical diagnosis and the prevention of cardiovascular disease, HeartGenetics will provide HEARTDECODE ® software and assays designed for use with the MassARRAY System. HEARTDECODE® software provides highly accurate and reproducible analysis with the integration of both genetic and pharmacogenetics data and medical guidelines.

Ana Teresa Freitas, Chief Executive Officer of HeartGenetics, commented

“We are excited to have the opportunity to partner with Agena Bioscience, whose MassARRAY technology provides an ideal platform for robust, cost-effective clinical diagnostics. Together we will be able to promote cardiovascular health to many patients with accurate, actionable and affordable testing.”

Click here to check the full press release at HeartGenetics’ website.